Hematol Oncol (2020) 38(4):56575
This chronic disease is linked with decreased life expectancy and a higher risk of developing serious health problems such as type 2 diabetes, heart disease, nonalcoholic fatty liver disease, sleep apnea, and certain cancers
The supernatant from the hypotonic solution was combined with the supernatant from the hypertonic solution, centrifuged to remove debris, and dialyzed against 20LmM Tris, pH 7.5 and 150LmM NaCl (Tris-buffered saline, TBS) overnight at 4 C
It highlights how empathy, intentional communication, and sustained engagement can directly influence adherence, trust, and long-term outcomes, showing how meaningful connection drives meaningful change
So when the numbers are that high, it's not just for diabetes anymore, right
The trajectory is now visible: SELECT showed semaglutide reducing MACE in obesity without diabetes FLOW showed semaglutide's renal benefit in T2D + CKD STEP-HFpEF showed semaglutide improving HF symptoms in HFpEF + obesity SUMMIT showed tirzepatide reducing CV death and HF events in HFpEF + obesity The medications we have called "obesity drugs" are increasingly looking like what they really are: metabolic therapies that treat the diseases driven by obesity cardiovascular disease, kidney disease, heart failure, MASH
